Sign inSubmit
ArticleMetrics
Research Article · Free to read · Published 6 June 2012

β 1, 3-Glucan in Cancer Treatment

Vaclav Vetvicka1 & J. Vetvickova1

American Journal of Immunology, Volume 8, Issue 2, pp. 38–43 · doi.org/10.3844/ajisp.2012.38.43

8,871 accesses7,959 downloads17 citations (Crossref)Metrics
Cite Check for updates

Abstract

Natural products, useful in preventing and/or treating various diseases, have been sought after throughout the man’s history. Despite some problems inherited from the natural source of glucans, there is extensive literature about their activities in animal tumor models. For the past 25 years, Japan has used several forms of mushroom-derived glucans in treating cancer patients. Additionally, close to twenty clinical trials are currently running in several countries, further suggesting the strong possibility of using glucans as an established anti-cancer drug.

Licence and reuse

Free to read. This article carries the publisher’s copyright, as printed on it: © 2012 Science Publications. It is free to read; ask us before reusing it.

How to reuse this article

Responses (0)

Have a comment on this research? Sign in to respond. Responses are moderated and published with your name and affiliation; the authors are invited to reply. How we use your dataWrite a response

About this article

Cite this article

Vetvicka, V. & Vetvickova, J. (2012). β 1, 3-Glucan in Cancer Treatment. American Journal of Immunology, 8(2), 38–43. https://doi.org/10.3844/ajisp.2012.38.43

Licence
© Science Publications
Issue
Volume 8, Issue 2
Policies
Editorial independenceUse of generative AIData availabilityAppeals and complaints
Version
Version of record
β 1, 3-Glucan in Cancer TreatmentAmerican Journal of Immunology · Volume 8, Issue 2 · pp. 38–43 · © Science PublicationsDownload